Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma

Glioblastoma (GBM), the most common and malignant brain tumor, is classified according to its isocitrate dehydrogenase (IDH) mutation status in the 2016 World Health Organization (WHO) brain tumor classification scheme. The standard treatment for GBM is maximal resection, radiotherapy, and Temozolom...

Descripción completa

Detalles Bibliográficos
Autores principales: Adilijiang, Alimu, Hirano, Masaki, Okuno, Yusuke, Aoki, Kosuke, Ohka, Fumiharu, Maeda, Sachi, Tanahashi, Kuniaki, Motomura, Kazuya, Shimizu, Hiroyuki, Yamaguchi, Junya, Wakabayashi, Toshihiko, Natsume, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749405/
https://www.ncbi.nlm.nih.gov/pubmed/31443404
http://dx.doi.org/10.3390/molecules24173046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749405/
https://www.ncbi.nlm.nih.gov/pubmed/31443404
http://dx.doi.org/10.3390/molecules24173046

Ejemplares similares